Tenofovir
- Generic Name
- Tenofovir
- Brand Names
- Vemlidy, Tenofovir disoproxil Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H14N5O4P
- CAS Number
- 147127-20-6
- Unique Ingredient Identifier
- W4HFE001U5
- Background
Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in ...
- Indication
Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.
To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, tenofovir alafenamide and tenofovir disoproxil.
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment
- First Posted Date
- 2010-02-05
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 144
- Registration Number
- NCT01063036
- Locations
- 🇪🇸
Local Institution, Valencia, Spain
Simvastatin for the Treatment of Chronic Hepatitis B
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2012-08-16
- Lead Sponsor
- Bader, Ted, M.D.
- Target Recruit Count
- 32
- Registration Number
- NCT00994773
- Locations
- 🇺🇸
VA Medical Center, Oklahoma City, Oklahoma, United States
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet
- Conditions
- Interventions
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2015-08-28
- Lead Sponsor
- CONRAD
- Target Recruit Count
- 18
- Registration Number
- NCT00984971
- Locations
- 🇺🇸
University of Pittsburgh Clinical Research Unit, Pittsburgh, Pennsylvania, United States
🇺🇸UCLA Center for HIV Prevention Research, Los Angeles, California, United States
A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both
- Conditions
- Interventions
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT00962871
Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women
- Conditions
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 24
- Registration Number
- NCT00869960
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
- Conditions
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 83
- Registration Number
- NCT00805675
- Locations
- 🇨🇳
Department of Medicine, Queen Mary Hospital, Hong Kong, China
A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT00651209
- Locations
- 🇹🇭
Novartis, Bangkok, Thailand
Characterization of Acute and Recent HIV-1 Infections in Zurich.
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 800
- Registration Number
- NCT00537966
- Locations
- 🇨🇭
University of Zurich, Zurich, Switzerland
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2019-06-05
- Target Recruit Count
- 35
- Registration Number
- NCT00524173
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
- Conditions
- Interventions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 629
- Registration Number
- NCT00410202
- Locations
- 🇺🇸
University Of Connecticut Health Center, Farmington, Connecticut, United States
🇹🇷Local Institution, Trabzon, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.